(chant)real world study of duvelisib in the treatment of non-hodgkin's lymphoma (nhl)

Conditions: Follicular Lymphoma; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Richter Syndrome; Marginal Zone Lymphoma; Peripheral T Cell Lymphoma; Diffuse Large B Cell Lymphoma

Summary: this is a multicenter, non-interventional and prospective real-world study to evaluate the efficacy and safety of duvelisib capsules in patients with non-hodgkin's lymphoma.

this is a multicenter, non-interventional and prospective real-world study to evaluate the efficacy and safety of duvelisib administered to subjects who have been diagnosed with non-hodgkin's lymphoma that is relapsed or refractory, including but not limited to the following subtypes : a) follicular lymphoma(fl); b) chronic lymphocytic leukemia/small lymphocytic lymphoma or richter syndrome(cll/sll or rs); c) marginal zone lymphoma(mzl); d) peripheral t-cell lymphoma(ptcl); e) diffuse large b-cell lymphoma(dlbcl).

Eligibility criteria:
inclusion criteria: * to participate in the study voluntarily and sign the informed consent (icf), with good compliance and cooperative visits; * patients must be ≥ 18 years of age (based on the date of signing the informed consent (icf)); * pathologically or histologically confirmed nhl including but not limited to the following subtypes: 1. follicular lymphoma (fl); 2. chronic lymphocytic leukemia/small lymphocytic lymphoma or richter syndrome (cll/sll or rs); 3. marginal zone lymphoma (mzl); 4. peripheral t-cell lymphoma (ptcl); 5. diffuse large b-cell lymphoma (dlbcl). * patients who have received at least one systemic chemotherapy and have relapsed at the end of the treatment or progressed during treatment; * must have adequate organ function defined by the following laboratory parameters: 1. bone marrow function: absolute neutrophil count (anc) ≥ 0.5 × 10\^9/l, platelet count (plt) ≥ 25 × 10\^9/l, blood transfusion can be used before medication; 2. liver and kidney function: aspartate transaminase (ast) and alanine aminotransferase (alt)≤5.0 × uln; 3. estimated creatinine clearance value ≥30 milliliters/minute (as determined by the cockcroft-gault method). * eastern cooperative oncology group (ecog) performance status of 0-2; * patients with infections should be treated first and then considered for enrollment when the infection is under control. exclusion criteria: * female subjects who are pregnant or breastfeeding; * estimated lifetime is less than 3 months; * in the investigator's judgment, patients who require but are unable to receive prophylactic treatment for pneumocystis or herpes simplex virus (hsv) prior to trial drug treatment; * history or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function; * prior history of drug-induced colitis or drug-induced interstitial pneumonia; * known hypersensitivity to duvelisib or its excipients; * administration of medications or foods that are strong inhibitors or inducers of cyp3a beginning 2 weeks prior to the first dose of duvelisib; * according to the judgement of the researcher, there are concomitant diseases that seriously endanger the safety of patients or affect the completion of the study.

Keywords: nhl; duvelisib